Vanguard Capital Management Acquires 5.09% Stake in Protagonist Therapeutics Inc

On April 30, 2026, Vanguard Capital Management LLC filed a Schedule 13G with the SEC, reporting a new 5.09% passive ownership stake in Protagonist Therapeutics Inc (PTGX). The filing indicates that as of the event date on March 31, 2026, Vanguard beneficially owns 3,250,003 shares of common stock. This position represents a significant increase from a previously reported 0% holding, crossing the 5% regulatory threshold. According to the filing, Vanguard Capital Management maintains sole dispositive power over all 3,250,003 shares, while holding sole voting power over 444,107 shares. The reporting entity includes various affiliates such as Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. The securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. This institutional entry underscores a growing investment interest from major asset managers in the Newark, California-based biotechnology company.